Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Namodenoson in Advanced Hepatocellular Carcinoma with CPB7 Cirrhosis
NCT05201404Phase 3Recruiting
- Sponsor
- Can-Fite BioPharma Ltd.
- Start
- Mar 2023
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of namodenoson in hepatocellular carcinoma (HCC), sponsored by Can-Fite BioPharma Ltd.. Started Mar 2023; status: recruiting.
02
Drugs
namodenoson
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05201404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05201404.